How effective is ixazomib in treating myeloma?

Ixazomib (trade name: Ninlaro), as an oral proteasome inhibitor, has demonstrated significant clinical effects in the treatment of multiple myeloma (MM) in recent years.

Ixazomib inhibits the activity of the proteasome by preferentially binding to the chymotrypsin-like active site of the 20Sproteasome β5 subunit, thereby blocking the protein degradation process in tumor cells. This inhibitory effect leads to the accumulation of abnormal proteins in cells, which in turn activates stress responses and induces tumor cell apoptosis. Compared with first-generation proteasome inhibitors, ixazomib is reversible and exhibits a superior safety profile in some aspects, such as a lower incidence of peripheral neuropathy.

Multiple international randomized double-blind clinical trials have confirmed the significant efficacy of ixazomib combined with lenalidomide and dexamethasone (IRd regimen) in the treatment of multiple myeloma. For example, in the TOURMALINE-MM1 trial, patients treated with the IRd regimen had significantly improved progression-free survival (PFS) compared with the control group. Specifically, the median PFS in the ixazomib group was 20.6 months compared with 14 in the placebo group. 7months, the hazard ratio (HR) is 0.66 (95% CI, 0.47-0.93; P = .016). This result shows that ixazomib combined with lenalidomide and dexamethasone can significantly extend the progression-free survival of patients and improve the treatment response rate.

Ixazomib has also shown some efficacy in patients with relapsed or refractory multiple myeloma. For example, in the C16010 clinical study, the overall response rate of ixazomib combined with lenalidomide and dexamethasone in patients with relapsed and / or refractory multiple myeloma who had received at least one prior therapy was approximately 78%. These data demonstrate the value of ixazomib in the treatment of relapsed and refractory multiple myeloma.

The evaluation of the efficacy of ixazomib in the treatment of multiple myeloma is not limited to progression-free survival, but also includes overall survival (OS), objective response rate (ORRORR span>), complete remission (CR) rate and very good partial remission (VGPR) rate. In multiple clinical trials, the IRd regimen has shown better efficacy than either single drug or placebo combined with lenalidomide and dexamethasone. For example, in some studies, the median OS of the ixazomib group was up to 25.8 months, while that of the placebo group was only 15.8 months; in terms of ORR, the ixazomib group was also significantly higher than the placebo group.

Although ixazomib has shown significant efficacy in the treatment of multiple myeloma, some side effects may occur during its use. These side effects mainly include gastrointestinal reactions (such as nausea, vomiting, diarrhea, etc.), rash, bone marrow suppression (such as neutropenia and thrombocytopenia), and peripheral neuropathy. However, the incidence of peripheral neuropathy with ixazomib is relatively low compared with first-generation proteasome inhibitors. In addition, most side effects are mild to moderate and can be alleviated with dose adjustment or supportive care.

Ixazomib is often used as first-line treatment or as part of treatment for relapsed or refractory multiple myeloma, in combination with drugs such as lenalidomide and dexamethasone. The doctor will develop a personalized treatment plan based on the patient's specific condition, physical condition and treatment response. The recommended dose of ixazomib is 4 mg taken orally once a week for three weeks followed by one week off. The administration method is simple and patients can take it by themselves at home.

Before using ixazomib, doctors should conduct a comprehensive assessment of the patient, including medical history, physical examination, laboratory tests, etc., to understand the patient's physical condition and potential risks.

During the treatment process, doctors should closely monitor changes in the patient's condition, including the occurrence of adverse reactions and evaluation of treatment effects. For patients who experience serious adverse reactions, the treatment plan should be adjusted promptly or corresponding supportive treatment should be given.

Patients should conduct treatment under the guidance of a doctor and never adjust the dosage or discontinue medication on their own. At the same time, patients should pay attention to their physical condition and seek medical attention promptly if they experience severe discomfort or side effects.